RT Journal Article
T1 Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain
A1 Martín Delgado, Mari Cruz
A1 Lucas Ramos, Pilar De
A1 García Botella, Alejandra María
A1 Cantón Moreno, Rafael María
A1 García Lledó, Alberto
A1 Hernández-Sampelayo Matos, Teresa
A1 Gómez Pavón, Javier
A1 González Del Castillo, Juan María
A1 Martín Sánchez, Francisco Javier
A1 Martínez-Sellés D Oliveira Soares, Manuel
A1 Molero García, José María
A1 Moreno Guillén, Santiago
A1 Rodríguez Artalejo, Fernando
A1 Ruiz Galiana, Julián
A1 Burillo Albizua, Almudena
A1 Muñoz García, Patricia Carmen
A1 Calvo Rey, Cristina
A1 Catalán González, María De Las Mercedes
A1 Cendejas Bueno, Emilio
A1 Halperin Benito, Ana Verónica
A1 Recio, Raúl
A1 Viñuela Benítez, Carmen
A1 Bouza Santiago, Emilio
AB Group A ß-hemolytic Streptococcus (S. pyogenes), also known as GAS, is a Gram-positive bacterium. It can be easily identified in the microbiology laboratory by its ability to hemolyse blood in culture media. This bacterium is highly virulent due to its production of enzymes and toxins, and its ability to cause immunologically mediated diseases such as rheumatic fever and post-streptococcal glomerulonephritis. GAS is the primary cause of bacterial pharyngotonsillitis, although it is typically a benign and non-invasive disease. However, it also has the potential to cause severe skin and soft tissue infections, necrotising fasciitis, bacteraemia and endocarditis, pneumonia and empyema, and streptococcal toxic shock syndrome, without any age or predisposition limits. The term invasive GAS disease (iGAS) is used to refer to this group of conditions. In more developed countries, iGAS disease has declined thanks to improved hygiene and the availability of antibiotics. For example, rheumatic fever has practically disappeared in countries such as Spain. However, recent data suggests a potential increase in some iGAS diseases, although the accuracy of this data is not consistent. Because of this, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has posed several questions about invasive GAS infection, especially its current situation in Spain. The committee has enlisted the help of several experts in the field to answer these questions. The following lines contain the answers that we have collaboratively produced, aiming to assist not only the members of ICOMEM but also anyone interested in this topic.
PB Sociedad Española de Quimioterapia
SN 0214-3429
SN 1988-9518
YR 2024
FD 2024-07-30
LK https://hdl.handle.net/20.500.14352/130157
UL https://hdl.handle.net/20.500.14352/130157
LA eng
NO Martín-Delgado, M. C., De Lucas Ramos, P., García-Botella, A., Cantón, R., García-Lledó, A., Hernández-Sampelayo, T., Gómez-Pavón, J., González Del Castillo, J., Martín Sánchez, F. J., Martínez-Sellés, M., Molero García, J. M., Moreno Guillén, S., Rodríguez-Artalejo, F. J., Ruiz-Galiana, J., Burillo, A., Muñoz, P., Calvo Rey, C., Catalán-González, M., Cendejas-Bueno, E., Halperin-Benito, V., … Bouza, E. (2024). Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 37(6), 454–471. https://doi.org/10.37201/req/067.2024
DS Docta Complutense
RD 15 ene 2026